• EI
  • Scopus
  • 中国科技期刊卓越行动计划项目资助期刊
  • 北大核心期刊
  • DOAJ
  • EBSCO
  • 中国核心学术期刊RCCSE A+
  • 中国精品科技期刊
  • JST China
  • FSTA
  • 中国农林核心期刊
  • 中国科技核心期刊CSTPCD
  • CA
  • WJCI
  • 食品科学与工程领域高质量科技期刊分级目录第一方阵T1
中国精品科技期刊2020
吴婷, 赵泽安, 陈演瑜, 李咏梅, 徐赫笛, 高尚, 庞建新. 大麦叶粉防治高尿酸血症及肾脏保护作用研究[J]. 食品工业科技, 2020, 41(22): 294-298,304. DOI: 10.13386/j.issn1002-0306.2020020085
引用本文: 吴婷, 赵泽安, 陈演瑜, 李咏梅, 徐赫笛, 高尚, 庞建新. 大麦叶粉防治高尿酸血症及肾脏保护作用研究[J]. 食品工业科技, 2020, 41(22): 294-298,304. DOI: 10.13386/j.issn1002-0306.2020020085
WU Ting, ZHAO Ze-an, CHEN Yan-yu, LI Yong-mei, XU He-di, GAO Shang, PANG Jian-xin. Anti-hyperuricemic and Nephroprotective Effects of Barley Leaf Powder in Hyperuricemic Mice[J]. Science and Technology of Food Industry, 2020, 41(22): 294-298,304. DOI: 10.13386/j.issn1002-0306.2020020085
Citation: WU Ting, ZHAO Ze-an, CHEN Yan-yu, LI Yong-mei, XU He-di, GAO Shang, PANG Jian-xin. Anti-hyperuricemic and Nephroprotective Effects of Barley Leaf Powder in Hyperuricemic Mice[J]. Science and Technology of Food Industry, 2020, 41(22): 294-298,304. DOI: 10.13386/j.issn1002-0306.2020020085

大麦叶粉防治高尿酸血症及肾脏保护作用研究

Anti-hyperuricemic and Nephroprotective Effects of Barley Leaf Powder in Hyperuricemic Mice

  • 摘要: 为探究大麦叶粉(BLP)对氧嗪酸钾诱导的高尿酸血症小鼠的降尿酸作用与肾脏保护作用及其作用机制,本研究通过腹腔注射氧嗪酸钾制备高尿酸血症小鼠模型,测定BLP对模型小鼠血清、尿液及粪便中的尿酸(UA)、血清肌酐(CR)及尿素氮(BUN)、血清与肝脏黄嘌呤氧化酶(XOD)肝脏活性的影响,观察HE染色后小鼠肾脏组织的病理学变化,检测各组小鼠尿酸转运蛋白mRNA的表达水平,以评估BLP的降尿酸作用与肾脏保护作用及其机制。结果显示,与模型组相比,200 mg/kg BLP能高度显著降低其血清UA水平(P<0.001),高度显著促进UA从尿液排出(P<0.001),极显著促进UA从粪便排出(P<0.01),同时高度显著降低血清与肝脏XOD活性、降低肝脏UA的生成(P<0.001)。此外,与模型组相比,200 mg/kg BLP能极显著降低高尿酸导致的血清CR水平升高(P<0.01),高度显著下调BUN水平(P<0.001),病理学分析结果也显示BLP能明显改善高尿酸导致的肾脏损伤。qRT-PCR实验结果显示,与模型组相比,200 mg/kg BLP可高度显著(P<0.001)下调肾脏尿酸重吸收蛋白URAT1、GLUT9,上调尿酸分泌蛋白OAT1的mRNA表达水平。综上,BLP的降尿酸和肾脏保护作用与其抑制XOD活性,下调URAT1、GLUT9,上调OAT1表达有关。

     

    Abstract: To investigate the anti-hyperuricemic and nephroprotective effects of barley leaf powder (BLP) in hyperuricemic mice and the underlying mechanisms, hyperuricemia in mice via intraperitoneal injection of potassium oxazinate were induced, and the effects by measuring the serum uric acid (UA), urine UA, feces UA, serum creatinine (CR), urea nitrogen (BUN), serum and hepatic xanthine oxidase (XOD) activities were evaluated, the pathological changes of the kidney tissues by HE staining were observed. Besides, the mRNA expression levels of urate transporters including urate transporter 1 (URAT1), glucose transporter 9 (GLUT9) and organic anion transporter 1 (OAT1) were detected to explore mechanisms of the anti-hyperuricemic and nephroprotective effects of BLP. Results showed that, compared with the model group, BLP at 200 mg/kg could highly significantly reduce the serum UA level (P<0.001), promote the excretion of UA from urine (P<0.001) and extremely significantly promote the UA excretion in feces (P<0.01). Meanwhile, BLP highly significantly reduced the serum and hepatic XOD activities as well as the production of liver UA at 200 mg/kg (P<0.001). In addition, compared with the model group, 200 mg/kg BLP could extremely significantly reduce the elevated serum CR (P<0.01) and highly significantly reduce the BUN levels caused by hyperuricemia (P<0.001), as proved by the pathological analysis of the kidney tissues. Data from qRT-PCR assays showed that 200 mg/kg BLP highly significantly (P<0.001) downregulated URAT1 and GLUT9 and upregulated OAT1 expressions compared with the model group. In summary, the anti-hyperuricemic and nephroprotective effects of BLP may be mediated by regulation of XOD, URAT1, GLUT9 and OAT1.

     

/

返回文章
返回